임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-05-28 15:33
논문번호 217
논문제목(영문) Two‑year clinical outcomes of zotarolimus‑ and everolimus‑eluting durable‑polymer‑coated stents versus biolimus‑eluting biodegradable‑polymer‑coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary inter
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Yong Hoon Kim, Ae-Young He
교신저자명 Yong Hoon Kim
공동저자명 Myung Ho Jeong,Byeong‑Keuk Kim,Sung‑Jin Hong,Dong‑Ho Shin, Jung‑Sun Kim, Young‑Guk Ko,Donghoon Choi, Myeong‑Ki Hong, Yangsoo Jang
게제년월일 2018-08-30
ISSN 0910-8327
Impact Factor 1.66
학술지명 HEART AND VESSELS
서지사항 0집 / 34권 / 2호,   페이지(237 - 250)
요약초록문
(Abstract) 입력		 There are limited data comparing the clinical outcomes among new-generation drug-eluting stents (DES) in acute myocardial infarction (AMI) patients with dyslipidemia after percutaneous coronary intervention (PCI). We thought to investigate 2-year clinical outcomes among durable-polymer (DP)-coated stents [zotarolimus eluting (ZES) and everolimus eluting (EES)] and biodegradable-polymer (BP)-coated biolimus-eluting stent (BES) in dyslipidemic AMI patients after PCI. Finally, a total 2403 enrolled patients were divided into ZES (n = 953), EES (n = 1145) or BES (n = 305) group. The primary endpoint was major adverse cardiac events (MACE) defined as total death (TD), cardiac death (CD), myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR) and non-TVR. The secondary endpoint was the incidence of definite or probable stent thrombosis (ST). The 2-year adjusted hazard ratio (HR) of MACE for ZES vs. EES [HR, 1.066; 95% confidence interval (CI) 0.752-1.511; p = 0.720], ZES vs. BES (HR 0.933; 95% CI 0.565-1.541; p = 0.786), EES vs. BES (HR 1.876; 95% CI 0.535-1.436; p = 0.600) and ZES/EES vs. BES (HR 0.929; 95% CI 0.591-1.462; p = 0.751) was similar. The cumulative incidences of ST were comparable (ZES vs. EES vs. BES = 1.1% vs. 0.9% vs. 1.1%, p = 0.675) and adjusted HR was not different. In addition, the 2-year adjusted HR of TD, CD, MI, TLR, TVR, and non-TVR was similar. The AMI patients with dyslipidemia receiving ZES, EES, or BES after PCI showed comparable safety and efficacy during 2-year follow-up periods. Therefore, DP-DES or BP-DES is equally acceptable in dyslipidemic AMI patients during PCI.

Keywords: Drug-eluting stents; Dyslipidemia; Myocardial infarction.
파일  C217. Two-year clinical outcomes of zotarolimus- and everolimus-eluting dur~.pdf (1.2M) DATE : 2021-05-28 15:33:01